Literature DB >> 26244153

Cervical cancer screening: A never-ending developing program.

Ciro Comparetto1, Franco Borruto1.   

Abstract

With the term "oncological screening", we define the overall performances made to detect early onset of tumors. These tests are conducted on a population that does not have any signs or symptoms related to a neoplasm. The whole population above a certain age, only one sex, only subjects with a high risk of developing cancer due to genetic, professional, discretionary reasons may be involved. Screening campaigns should be associated, when risk factors that can be avoided are known, with campaigns for the prevention of cancer by means of suitable behavior. The goal of cancer screening cannot however be limited to the diagnosis of a greater number of neoplasms. Screening will be useful only if it leads to a reduction in overall mortality or at least in mortality related to the tumor. Screening should then allow the diagnosis of the disease at a stage when there is a possibility of healing, possibility that is instead difficult when the disease is diagnosed at the appearance of signs or symptoms. This is the reason why not all campaigns of cancer screening have the same effectiveness. In Italy, every year there are about 150000 deaths due to cancer. Some of these tumors can be cured with a very high percentage of success if diagnosed in time. Cervical cancer can be diagnosed with non-invasive tests. The screening test used all over the world is Papanicolaou (Pap) test. This test may be carried out over the entire healthy population potentially exposed to the risk of contracting cancer. Public health has begun the screening campaigns in the hope of saving many of the approximately 270000 new cases of cancer reported each year. Screening is done following protocols that guarantee quality at the national level: these protocols are subject to change over time to reflect new realities or to correct any errors in the system. A simplified sketch of a possible route of cancer screening is as follows: (1) after selecting the target population, for example all women between 25 and 64 years (in the case of monitoring of cervical cancer), an invitation letter with the date and time of the appointment, planned according to the acceptance capacity of the hospital, is sent to all individuals; (2) an examination, which depending on the individual and the type of cancer to be monitored, for example, can be a Pap smear, is performed and the patient can go home; (3) once available the results of examinations, if negative, they shall be communicated to the person concerned that will be notified by mail and will be recalled for a second test at a few years of distance, in the case of non-negativity, instead, the patient is contacted by telephone and informed of the need to carry out further examinations: it is said that the patient is in the "phase two" of the screening pathway; (4) in phase two, reached by only a small portion of the interested parties (usually less than 3%-5%), more in-depth tests are carried out, which, depending on the individual and the type of cancer, can be: cytological and colposcopic examinations, the removal of a fragment of tissue (biopsy) and subsequent histological examination, additional tests such as ultrasound, radiography, or others such as computerized tomography, magnetic resonance imaging, positron emission tomography, etc., in case of negativity, the concerned person will be called for new control tests at a a few years of distance, in case of non-negativity, it will be proposed instead an oncologic therapeutic plan and/or surgery to treat the diagnosed tumor; and (5) once the treatment plan is completed, the individual enters the follow-up protocol, which is monitored over time to see if the tumor has been completely removed or if instead it is still developing. Cervical cancer is undoubtedly the most successful example of a cancer screening campaign. Paradoxically, its effectiveness is one of the strongest reasons to criticize the usefulness of vaccination against human papillomavirus (HPV) in countries where the screening service with Pap test is organized in an efficient manner. Cervical cancer screening protocols are directed to sexually active women aged 25-64 years: they provide the Pap test performed by examining under a microscope or by staining with a specific "thin prep" the material taken from the cervix with a small spatula and a brush. It is recommended to repeat the test every two or three years. It is important to emphasize that women vaccinated against HPV must continue the screening with Pap test. Although some screening programs (e.g., Pap smears) have had remarkable success in reducing mortality from a specific cancer, any kind of screening is free from inherent limitations. The screening methods are in fact applied to large parts of the apparently healthy population. In particular, the limits for certain cancers may be as obvious as to prohibit the introduction of an organized screening program. Potential limitations of organized screenings are basically of two types: organizational and medical. The limits of organizational type relate to the ability of a program to recruit the whole target population. Although well organized, a screening program will hardly be able to exceed a coverage of 70%-80% of the target population, and in fact the results of the current programs are often much smaller. The limits of medical type are represented by the possibility of reducing the overall mortality, or specific mortality, using a specific screening campaign.

Entities:  

Keywords:  Cervical cancer; Human papillomavirus test; Papanicolaou test; Screening; Vaccination

Year:  2015        PMID: 26244153      PMCID: PMC4517336          DOI: 10.12998/wjcc.v3.i7.614

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  33 in total

Review 1.  Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences.

Authors:  Rana S Hoda; Kristina Loukeris; Fadi W Abdul-Karim
Journal:  Diagn Cytopathol       Date:  2012-04-17       Impact factor: 1.582

Review 2.  The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.

Authors:  Marc Arbyn; Jolien Roelens; Kate Cuschieri; Jack Cuzick; Ann Szarewski; Sam Ratnam; Miriam Reuschenbach; Suzanne Belinson; Jerome L Belinson; Joseph Monsonego
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

3.  Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia.

Authors:  Catherine Sauvaget; Richard Muwonge; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2012-12-22       Impact factor: 3.561

Review 4.  Quality improvement opportunities in gynecologic cytologic-histologic correlations: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 4.

Authors:  Barbara A Crothers; Bruce A Jones; Leigh Ann Cahill; Ann T Moriarty; Dina R Mody; William D Tench; Rhona J Souers
Journal:  Arch Pathol Lab Med       Date:  2013-02       Impact factor: 5.534

Review 5.  A framework provided an outline toward the proper evaluation of potential screening strategies.

Authors:  Wim J Adriaensen; Cathy Matheï; Frank J Buntinx; Marc Arbyn
Journal:  J Clin Epidemiol       Date:  2013-02-06       Impact factor: 6.437

Review 6.  Diagnostic tests for the detection of human papillomavirus-associated cervical lesions.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Human papillomavirus as a target for management, prevention and therapy.

Authors:  Emma J Crosbie; Henry C Kitchener
Journal:  Int J Hyperthermia       Date:  2012-06-12       Impact factor: 3.914

Review 8.  Cervical cancer screening in Mediterranean countries: implications for the future.

Authors:  K Syrjänen; L Di Bonito; L Gonçalves; L Murjal; M Santamaria; V Mahovlic; P Karakitsos; B Onal; F C Schmitt
Journal:  Cytopathology       Date:  2010-08-15       Impact factor: 2.073

Review 9.  A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening.

Authors:  Insiyyah Y Patanwala; Heidi M Bauer; Justin Miyamoto; Ina U Park; Megan J Huchko; Karen K Smith-McCune
Journal:  Am J Obstet Gynecol       Date:  2012-11-15       Impact factor: 8.661

Review 10.  Prospective and retrospective review of gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 2.

Authors:  Jennifer A Brainard; George G Birdsong; Tarik M Elsheikh; David A Hartley; Kalyani Naik; Margaret H Neal; Rhona J Souers; Michael R Henry
Journal:  Arch Pathol Lab Med       Date:  2013-02       Impact factor: 5.534

View more
  7 in total

1.  Characteristic findings of high-grade cervical intraepithelial neoplasia or more on magnifying endoscopy with narrow band imaging.

Authors:  Kunihisa Uchita; Kenji Kanenishi; Koki Hirano; Hideki Kobara; Noriko Nishiyama; Ai Kawada; Shintaro Fujihara; Emi Ibuki; Reiji Haba; Yohei Takahashi; Yuka Kai; Kenji Yorita; Hirohito Mori; Jun Kunikata; Naoki Nishimoto; Toshiyuki Hata; Tsutomu Masaki
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

2.  Spousal support and knowledge related to cervical cancer screening: Are Sub-Saharan African immigrant men interested?

Authors:  Adebola Adegboyega; Mollie Aleshire; Mark Dignan; Jennifer Hatcher
Journal:  Health Care Women Int       Date:  2019-05-14

3.  BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity.

Authors:  Wei Zou; Xiangdong Ma; Wei Hua; Biliang Chen; Yanhong Huang; Detang Wang; Guoqing Cai
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

4.  Proteomics-based identification of VDAC1 as a tumor promoter in cervical carcinoma.

Authors:  Changlin Zhang; Wencheng Ding; Yuan Liu; Zheng Hu; Da Zhu; Xiaoli Wang; Lan Yu; Liming Wang; Hui Shen; Weican Zhang; Ci Ren; Kezhen Li; Danhui Weng; Wuguo Deng; Ding Ma; Hui Wang
Journal:  Oncotarget       Date:  2016-08-09

5.  Frequency of pap smear among doctors: A pilot study.

Authors:  Lamia Yusuf
Journal:  Pak J Med Sci       Date:  2020 May-Jun       Impact factor: 1.088

6.  Knowledge of Cervical Cancer, Human Papilloma Virus (HPV) and HPV Vaccination Among Women in Northeast China.

Authors:  Yu-E Ning; Yao Liu; Xiao-Yu Xu; Xin-Yu Zhang; Ning Wang; Li-Qiang Zheng
Journal:  J Cancer Educ       Date:  2020-12       Impact factor: 2.037

7.  TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions.

Authors:  Oscar Del Moral-Hernández; Daniel Hernández-Sotelo; Luz Del Carmen Alarcón-Romero; Miguel Angel Mendoza-Catalán; Eugenia Flores-Alfaro; Yaneth Castro-Coronel; Julio Ortiz-Ortiz; Marco Antonio Leyva-Vázquez; Carlos Ortuño-Pineda; Wendy Castro-Mora; Berenice Illades-Aguiar
Journal:  BMC Cancer       Date:  2021-01-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.